RecruitingNCT06416995

Serum Vasohibin, Cardiotrophin, Endocan & Perinatal Outcomes

Investigation of First Trimester Serum Vasohibin-1, Vasohibin-2, Cardiotrophin-1 and Endocan Concentrations in Predicting Adverse Perinatal Outcomes


Sponsor

Umraniye Education and Research Hospital

Enrollment

88 participants

Start Date

Mar 3, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Investigation of the relationship between maternal serum vasohibin-1, vasohibin-2, cardiotrophin -1 and endocan concentrations at the 11th and 14th weeks of gestation and adverse perinatal outcomes.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 39 Years

Plain Language Summary

Simplified for easier understanding

This study is measuring levels of specific proteins in the blood during early pregnancy to see if they can predict serious pregnancy complications like preeclampsia (dangerous high blood pressure in pregnancy), preterm birth, or growth problems in the baby. The proteins being studied are vasohibin, cardiotrophin, and endocan. **You may be eligible if...** - You are pregnant with a single baby (not twins or more) - You had your first trimester screening (at 11–14 weeks) and were found to be low-risk - You conceived naturally (not through IVF or other assisted reproduction) - You had no pre-existing health conditions before pregnancy - You have no uterine (womb) abnormalities **You may NOT be eligible if...** - You smoke - You were found to be high-risk at the first trimester screening - You are carrying multiple babies (twins, triplets, etc.) - You conceived using IVF or other assisted reproductive methods - You have any medical condition that started before pregnancy - You have any uterine abnormalities Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTfirst trimester serum diagnostic test

First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes


Locations(1)

Ümraniye Eğitim ve Araştırma Hastanesi

Istanbul, Ümraniye, Turkey (Türkiye)

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06416995


Related Trials